Heron Therapeutics, Inc. (HRTX) Reaches $33.85 After 4.00% Up Move; ALFA-LAVAL AB ORDINARY SHARES SWEDEN (ALFVF) Shorts Lowered By 7.83%

May 17, 2018 - By Richard Conner

ALFA-LAVAL AB ORDINARY SHARES SWEDEN (OTCMKTS:ALFVF) had a decrease of 7.83% in short interest. ALFVF’s SI was 645,200 shares in May as released by FINRA. Its down 7.83% from 700,000 shares previously. With 400 avg volume, 1613 days are for ALFA-LAVAL AB ORDINARY SHARES SWEDEN (OTCMKTS:ALFVF)’s short sellers to cover ALFVF’s short positions. The SI to ALFA-LAVAL AB ORDINARY SHARES SWEDEN’s float is 0.22%. It closed at $23.54 lastly. It is down 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) is a huge mover today! The stock increased 5.45% or $1.75 during the last trading session, reaching $33.85. About 602,358 shares traded. Heron Therapeutics, Inc. (NASDAQ:HRTX) has risen 87.03% since May 17, 2017 and is uptrending. It has outperformed by 75.48% the S&P500.The move comes after 9 months positive chart setup for the $2.44B company. It was reported on May, 17 by Barchart.com. We have $35.20 PT which if reached, will make NASDAQ:HRTX worth $97.44 million more.




Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company has market cap of $2.44 billion. The companyÂ’s product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single subcutaneous injection. It currently has negative earnings. It offers SUSTOL extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens.

Among 15 analysts covering Heron Therapeutics (NASDAQ:HRTX), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics had 44 analyst reports since August 3, 2015 according to SRatingsIntel. On Monday, March 26 the stock rating was maintained by Northland Capital with “Buy”. Cantor Fitzgerald maintained the stock with “Buy” rating in Sunday, April 22 report. Bank of America initiated Heron Therapeutics, Inc. (NASDAQ:HRTX) rating on Wednesday, September 2. Bank of America has “Buy” rating and $46.0 target. The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) has “Buy” rating given on Thursday, December 14 by Oppenheimer. Mizuho maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) rating on Tuesday, November 7. Mizuho has “Buy” rating and $28.0 target. The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) has “Buy” rating given on Monday, March 19 by Cantor Fitzgerald. Evercore initiated the stock with “Buy” rating in Thursday, April 5 report. The stock has “Buy” rating by Jefferies on Wednesday, September 23. The firm earned “Buy” rating on Tuesday, March 27 by Oppenheimer. Cowen & Co maintained it with “Buy” rating and $40.0 target in Monday, November 6 report.

Another recent and important Heron Therapeutics, Inc. (NASDAQ:HRTX) news was published by Nasdaq.com which published an article titled: “Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith …” on May 14, 2018.

Analysts await Heron Therapeutics, Inc. (NASDAQ:HRTX) to report earnings on August, 8. They expect $-0.69 EPS, up 13.75% or $0.11 from last year’s $-0.8 per share. After $-0.81 actual EPS reported by Heron Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -14.81% EPS growth.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts